Churchill Capital Corp X

First public quarter for the deSPAC: the $569 million cash pile is real but the operating loss quadrupled year over year and $40 million of 2026 revenue implies a very high multiple; the share count jumped 12x from the merger and preferred conversion.

Quantifies the sponsor's continuing post-close economics: $1 million a year in advisory fees to a Michael Klein affiliate for two years plus success-based transaction fees, alongside a board seat held by a designee the company itself deems non-independent.

This is the document that puts the entire 121.8 million share insider and PIPE block into registered, freely sellable form roughly eight weeks after the February 13, 2026 closing — a resale overhang several times the size of the former public float, against a stock then at $11.89.

First hard financials from the Churchill Capital Corp X deSPAC: real but small revenue ($32.5M in 2025 growing to a guided $40M in 2026) against roughly $28M of annual non-GAAP operating losses, so the quantum story is cash-consuming and guidance growth of about 23% is modest relative to the valuation SPAC investors underwrote.

Confirms the CCCX deSPAC is complete: the SPAC is now NYSE-listed quantum company Infleqtion (INFQ) with 216.5 million shares outstanding, so any SPAC-stage tracking of CCCX should be closed out as of February 13, 2026.

Standard post-deSPAC transition from the SPAC's shell auditor to a Big Four firm, confirming the Churchill Capital X / ColdQuanta combination has closed and Infleqtion now trades on the NYSE as INFQ.

Re-filing of the definitive merger agreement five days after the February 12, 2026 shareholder approval, consistent with the closing of the Infleqtion business combination.

Duplicate filing of the vote result that approved the Infleqtion deSPAC; no additional facts beyond the parallel 8-K.

Final shareholder approval of the Churchill Capital X / Infleqtion quantum-computing deSPAC and the Cayman-to-Delaware domestication, clearing the way for the company to list as INFQ.

Sets the exact date CCCX ceased trading on Nasdaq (February 13, 2026) and the NYSE start date for the successor — the listing-transfer half of the deSPAC lifecycle.

S-4 effectiveness plus a fixed February 12, 2026 vote date; the $540 million gross proceeds figure is explicitly a no-redemption number, and actual post-close cash was about $569 million including the PIPE.

The definitive terms of the largest deal in this batch: $1.8 billion equity value at a $10.00 reference plus a $126.5 million PIPE, against a sponsor promote of 10.35 million shares acquired for roughly $31,000 total. The 0.347 exchange ratio and $10.00 pricing set the basis for the shares that later traded between $11.89 and $16.95 post-close.

Quantifies the Infleqtion deal funding — over $540 million gross including a $125 million+ PIPE — and marks the S-4 filing that led to the February 12, 2026 shareholder approval.

The S-4 is the formal registration step for the Infleqtion deSPAC: a 41.4 million-unit ($414 million) trust against 10,350,000 founder shares bought for about $22,000, i.e. a 25% promote on the pre-redemption base.

What changed: Infleqtion (post-CCCX merger, now NYSE: INFQ) reported Q2 2026 revenue of $12.6M (+116% YoY) and raised full-year 2026 revenue guidance to ~$43M, with $582M in cash and securities and no debt as of June 30, 2026. The company received a U.S. Commerce Department LOI for up to $100M in proposed funding and remains on track for 30 logical qubits in 2026. Why it matters: This is the first full quarterly report since the CCCX merger closed, showing the de-SPAC target executing commercially with strong revenue growth and a substantial cash runway from the $528M in net Business Combination proceeds. GAAP operating loss widened to $30.6M from $10.1M, reflecting heavy investment in scaling, with 224.7M shares outstanding versus 17.4M pre-merger.

What changed: Prospectus Supplement No. 4 (dated July 14, 2026) to the April 9, 2026 resale prospectus on Form S-1 (No. 333-294802) of the post-combination company, filed solely to update selling-securityholder information after entities affiliated with Global Frontier distributed 23,251,796 shares in kind to limited partners on July 10, 2026 (largest recipients: S G Foundation 11,573,878 shares, FW Global Frontiers Investors LP 2,418,323, LAD Trust 2,085,798, Capital Partnership (CMB) LP 1,943,807, W. Grant Dollens 1,994,448, William E. Greener 1,871,018). The prospectus covers up to 121,829,432 resale shares — 12,654,760 PIPE shares from September 8, 2025 subscription agreements, 10,350,000 Sponsor founder shares (including 1,500,000 unvested at Closing that re-vest on the Triggering Event), 300,000 CCX private placement shares and 98,449,672 shares issued to former ColdQuanta (Infleqtion) holders — plus 10,425,000 warrant shares. Common stock and public warrants trade on NYSE as INFQ and INFQ WS; on July 14, 2026 the stock last traded at $10.45 and warrants at $5.35. Why it matters: Confirms the Churchill Capital Corp X / Infleqtion combination has closed and the successor trades on NYSE as INFQ. The registered resale overhang is 121.8 million shares against a stock at $10.45, and Global Frontier's in-kind distribution puts 23.25 million previously locked shares into the hands of individual LPs who face no coordinated sale restriction.

What changed: Prospectus Supplement No. 3 (dated June 5, 2026) to the April 9, 2026 resale prospectus on Form S-1 (No. 333-294802), filed solely to update selling-securityholder information for the June 2, 2026 in-kind distribution of 3,825,935 shares by entities affiliated with Maverick Capital to its limited partners; recipients include Matthew Kinsella (7,814,538 shares registered), Cohasset VC Ltd (1,386,242), Illiquid Markets 1888 Fund LLC (331,507), Singer-Kapp Revocable Trust (324,320) and Premera Blue Cross (215,053). The underlying prospectus covers up to 121,829,432 resale shares plus 10,425,000 warrant shares. Common stock and public warrants trade on NYSE as INFQ and INFQ WS; on June 4, 2026 the last reported prices were $16.95 per share and $8.88 per warrant. Why it matters: Shows the post-deSPAC Infleqtion stock at $16.95 in early June 2026, well above the $10 SPAC reference, while sponsor and legacy-holder shares continue to be distributed out of funds to individual LPs who can sell into the registered 121.8 million share overhang.